Welcome to our dedicated page for Heron Therapeutics news (Ticker: HRTX), a resource for investors and traders seeking the latest updates and insights on Heron Therapeutics stock.
Heron Therapeutics, Inc. reports commercial and financial developments for a commercial-stage biotechnology business focused on acute care and oncology products. News commonly covers revenue performance and guidance for the Acute Care franchise, including ZYNRELEF and APONVIE, as well as oncology product updates involving CINVANTI and the broader product portfolio.
Company updates also address APONVIE’s role as an FDA-approved IV NK-1 receptor antagonist for prevention of postoperative nausea and vomiting in adults, ZYNRELEF product-handling initiatives for hospital and ambulatory surgical center use, distribution and sales-force activity, intellectual-property matters, and board or governance changes.
Heron Therapeutics has entered into a cooperation agreement with shareholders Rubric Capital and Velan Capital, leading to the appointment of three independent directors to its board, expanding it to eight members, with seven being independent. The new directors include Craig Collard, Adam Morgan, and Kevin Kotler, while outgoing directors Stephen Davis and Kimberly Manhard will depart. Additionally, Heron will separate the roles of Chairman and CEO following the 2023 Annual Meeting. The company highlights growth expectations for its products ZYNRELEF and APONVIE, indicating confidence in enhancing shareholder value.
Heron Therapeutics reported remarkable growth with 2022 net product sales reaching $106.7 million, a 24% increase from 2021. Fourth-quarter sales for ZYNRELEF rose by 40% to approximately $3.8 million. The oncology care franchise achieved full-year 2022 sales of around $96.6 million, surpassing guidance. For 2023, guidance suggests sales of $99 million to $103 million. The submission of a supplemental NDA for ZYNRELEF aims to expand its indications further, while new product APONVIE is set to launch soon.
Heron Therapeutics (HRTX) submitted a supplemental New Drug Application (sNDA) to broaden the indication for ZYNRELEF in soft tissue and orthopedic procedures. This aims to significantly increase its target surgical procedures to 14 million. The recently passed omnibus spending bill, effective January 1, 2025, will provide separate reimbursement for non-opioid treatments like ZYNRELEF, extending until December 31, 2027. These developments position ZYNRELEF for greater uptake in hospital systems, enhancing postoperative pain management while reducing opioid reliance.
Heron Therapeutics (HRTX) reported Q3 2022 financials, showing strong net product sales growth. ZYNRELEF's sales reached $2.7 million, reflecting an 18% quarterly demand increase. The oncology care franchise achieved net sales of $23.9 million, up 13% year-over-year, sustaining a projected $93 million to $95 million for full-year 2022. APONVIE received FDA approval, with U.S. launch expected in Q1 2023, targeting postoperative nausea and vomiting. Despite a net loss of $41.9 million, improvements in operating cash usage were noted.
Heron Therapeutics, Inc. (Nasdaq: HRTX) will host a conference call and webcast on November 8, 2022, at 4:30 p.m. ET, to discuss its third quarter 2022 financial results and recent business highlights. Investors can join the call by dialing (646) 307-1963 for domestic calls or (800) 715-9871 for international calls, using the passcode 4433557. The event will also be available via webcast on Heron's website, with an archived version accessible for 60 days post-event.
Heron Therapeutics has received FDA approval for APONVIE (aprepitant), the first intravenous formulation for preventing postoperative nausea and vomiting (PONV) in adults. Administered as a single 30-second IV injection, APONVIE achieves therapeutic levels rapidly and maintains them for at least 48 hours. Clinical studies showed APONVIE was more effective than standard treatments, reducing vomiting in patients post-surgery. This launch expands Heron's acute care portfolio, targeting approximately 36 million surgical procedures annually in the U.S.
Heron Therapeutics, Inc. (Nasdaq: HRTX) announced a private placement to raise approximately $76.5 million by selling 16,129,032 shares of common stock at $3.10 per share. This funding, led by Deep Track Capital, LP, aims to support the company's acute care and oncology franchises, including the anticipated launch of HTX-019 for postoperative nausea and vomiting. The placement is expected to close on August 11, 2022. The company also plans to file a registration statement with the SEC for the resale of these shares.
Heron Therapeutics reported significant growth in the second quarter of 2022, with ZYNRELEF product sales soaring by 140% sequentially, reaching $2.5 million. The oncology care franchise saw net sales climb 12% to $25.1 million, prompting an increase in full-year sales guidance to $93 million to $95 million. The company anticipates over $50 million in cost reductions due to restructuring efforts. Pro-forma cash post-private placement stands at $158.7 million, ensuring a cash runway through 2024.
Heron Therapeutics (HRTX) will host a conference call on August 9, 2022, at 8:30 a.m. ET to discuss its second quarter 2022 financial results and recent business developments. The call is accessible via phone or webcast, with an archive available for 60 days post-call. Heron focuses on developing therapeutic innovations to enhance medical care, particularly for acute care and oncology patients. Interested parties can find more details on the company's website.
Summary not available.